Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical <scp>ASCVD</scp> Study
Semaglutide 2.4 mg was associated with a significantly reduced risk of MACE and other obesity-related outcomes, extending prior evidence of benefits to a broader clinical ASCVD population.
Authors
- Kerem Özer
- Joanna Boland (ORCID: https://orcid.org/0000-0001-7858-979X)
- Andrea Traina
- Kim G. Smolderen (ORCID: https://orcid.org/0000-0001-6104-6254)
- Carlos Mena‐Hurtado (ORCID: https://orcid.org/0000-0002-4954-5672)
- Victoria Divino
- Jinlin Song
- Yan Chen
- Michael G. Nanna
- Filip K. Knop
- Zhenxiang Zhao
Institutions
- Novo Nordisk (Denmark) (DK)
- Yale University (US)
- Novo Nordisk (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1111/dom.70686
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00